دورية أكاديمية
Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland
| العنوان: | Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland |
|---|---|
| المؤلفون: | Lynda M. McSorley, Mehala Tharmabala, Fathiya Al Rahbi, Fergus Keane, Denis Evoy, James G. Geraghty, Jane Rothwell, Damian P. McCartan, Megan Greally, Miriam O’Connor, Deirdre O’Mahony, Maccon Keane, Michael John Kennedy, Seamus O’Reilly, Steve J. Millen, John P. Crown, Catherine M. Kelly, Ruth S. Prichard, Cecily M. Quinn, Janice M. Walshe |
| المصدر: | Current Oncology, Vol 31, Iss 3, Pp 1302-1310 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | breast cancer, gene expression profiling, prognostic factors, cost analysis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background: This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper pertains to lobular breast cancer. Methods: A retrospective, observational study was undertaken between 2011 and 2019 on a cross-section of hormone receptor-positive (HR+), HER2-negative, lymph node-negative, early-stage breast cancer patients. All patients had ILC and had RS testing in Ireland. The patient population is representative of the national population. Patients were classified as low (RS ≤ 25) or high (RS > 25) risk. Patients aged ≤50 were stratified as low (RS 0–15), intermediate (RS 16–25), or high risk (RS > 25). Results: A total of 168 patients were included, most of whom had grade 2 (G2) tumors (n = 154, 92%). Overall, 155 patients (92.3%) had low RS (≤25), 12 (7.1%) had high RS (>25), and 1 (0.6%) had unknown RS status. In 29 (17.5%) patients aged ≤50 at diagnosis, RS was ≤15 in 16 (55%), 16–20 in 6 (21%), 21–25 in 5 (17%), >25 in 1 (3.5%), and unknown in 1 (3.5%). Post RS testing, 126 patients (78%) had a change in chemotherapy recommendation; all to hormone therapy. In total, only 35 patients (22%) received chemotherapy. RS testing achieved a 75% reduction in chemotherapy use, resulting in savings of €921,543.84 in treatment costs, and net savings of €387,283.84. Conclusions: The use of this test resulted in a 75% reduction in chemotherapy and a significant cost savings in our publicly funded health system. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1718-7729 1198-0052 |
| Relation: | https://www.mdpi.com/1718-7729/31/3/98; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729 |
| DOI: | 10.3390/curroncol31030098 |
| URL الوصول: | https://doaj.org/article/c7e991104cdb4851bf2dfdfc09b20e5d |
| رقم الأكسشن: | edsdoj.7e991104cdb4851bf2dfdfc09b20e5d |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 17187729 11980052 |
|---|---|
| DOI: | 10.3390/curroncol31030098 |